Research Article: ISI matsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Abstract:
This study aimed to determine the most efficacious insulin resistance (IR) indices to predict metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM).
This cross-sectional study included 1,587 patients with T2DM. MASLD was defined by abdominal ultrasound findings. Liver fibrosis risk was assessed with FIB-4. All participants underwent a 100?g standard steamed bread meal test. We analyzed basal IR indices (HOMA-IR, QUICKI, IAI, Bennett ISI) and post-stimulation IR indices (ISI matsuda , ISI 0,120 ) to explore their associations with MASLD and liver fibrosis.
Participants were categorized into four groups according to IR indices quartiles. Among post-stimulation IR indices, MASLD detection rates in ISI matsuda Q1–Q4 groups were 65.7, 54.2, 37.0, and 22.2%, respectively. Logistic regression analysis revealed significantly increased odds ratios (ORs) for MASLD in ISI matsuda Q1-Q3 groups compared to the Q4 group (OR?=?3.63, 2.53, and 1.53, respectively; all p <?0.05). Similar results were observed across other IR indices (all p <?0.05). There were no statistically significant differences in the detection rates of liver fibrosis or the ORs among the quartile groups of the IR indices (all p >?0.05). ROC curve analysis showed that ISI matsuda had superior predictive power for MASLD in patients with T2DM (AUC?=?0.701). Based on these findings, a risk prediction model for MASLD in the T2DM population was constructed using age, body mass index (BMI), alanine aminotransferase (ALT), triglycerides (TG), and 2-h postprandial C-peptide (2?h CP).
Among the IR indices, ISI matsuda demonstrated the strongest correlation and highest predictive value for MASLD in T2DM.
Introduction:
This study aimed to determine the most efficacious insulin resistance (IR) indices to predict metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM).
Read more